Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
We evaluated the safety and efficacy of an optimized adeno-associated virus (AAV; AAV2.RPE65) in animal models of the RPE65 form of Leber congenital amaurosis (LCA). Protein expression was optimized by addition of a modified Kozak sequence at the translational start site of hRPE65. Modifications in AAV production and delivery included use of a long stuffer sequence to prevent reverse packaging from the AAV inverted-terminal repeats, and co-injection with a surfactant. The latter allows consistent and predictable delivery of a given dose of vector. We observed improved electroretinograms (ERGs) and visual acuity in Rpe65 mutant mice. This has not been reported previously using AAV2 vectors. Subretinal delivery of 8.25 x 10(10) vector genomes in affected dogs was well tolerated both locally and systemically, and treated animals showed improved visual behavior and pupillary responses, and reduced nystagmus within 2 weeks of injection. ERG responses confirmed the reversal of visual deficit. Immunohistochemistry confirmed transduction of retinal pigment epithelium cells and there was minimal toxicity to the retina as judged by histopathologic analysis. The data demonstrate that AAV2.RPE65 delivers the RPE65 transgene efficiently and quickly to the appropriate target cells in vivo in animal models. This vector holds great promise for treatment of LCA due to RPE65 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jean Bennett's group enhanced safety and maximized the therapeutic effect by adding a stuffer sequence for rAAV product hRPE65v2 [39,226].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [226]
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationDOUGLAS, R. M., ALAM, N. M., SILVER, B. D., MCGILL, T. J., TSCHETTER, W. W., & PRUSKY, G. T. (2005) · Visual Neuroscience · doi:10.1017/s0952523805225166 · Cited by 405
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Lyubarsky, A. L., Falsini, B., Pennesi, M. E., Valentini, P., & Pugh, E. N. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00442.1999 · Cited by 273
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Aguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationPang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings
Lyubarsky, A., & Pugh, E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00563.1996 · Cited by 225
Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction.
Bennett, J., Duan, D., Engelhardt, J. F., & Maguire, A. M. (1997) · PubMed · Cited by 204
Self-citation
Cited by
Items 101–200 of 268
AAV-PHP.eB transduces both the inner and outer retina with high efficacy in mice
Palfi, A., Chadderton, N., Millington‐Ward, S., Post, I. J. M., Humphries, P., Kenna, P. F., & Farrar, G. J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.016 · Cited by 37
“Recombinant AAVs were generated using a triple transfection method,(66) and then purified by differential precipitation and cesium gradient centrifugation.(65,67,68) Genomic titres (viral genomes/mL; vg/mL) were determined by qPCR using EGFPspecific primers (forward: 50-TTCAAGGAGGACGGCAACATCC, reverse: 50-AGCTGCACGCTG…”
MethodLee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
Self-citationAnnear, M. J., Mowat, F. M., Bartoe, J. T., Querubin, J., Azam, S. A., Basche, M., Curran, P. G., Smith, A. J., Bainbridge, J. W. B., Ali, R. R., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.146 · Cited by 34
“Similar dramatic improvements in retinal function were achieved in young Rpe65 -/- and Rpe65 rd12/rd12 mice treated by rAAV-RPE65 subretinal injection (Dejneka et al., 2004; Pang et al., 2006; Roman et al., 2007; Bennicelli et al., 2008).”
Mary, B., Maurya, S., Kumar, M., Bammidi, S., Kumar, V. S., & Jayandharan, G. R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00959 · Cited by 34
Miyadera, K., Kato, K., Boursnell, M. E. G., Mellersh, C. S., & Sargan, D. R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9384-9 · Cited by 35
“Of the genes within the second RD interval, LRAT is a strong candidate gene based on its involvement in severe EORDs in human patients (Thompson et al. 2001).”
InfluentialPreliminary Results of Gene Therapy for Retinal Degeneration
Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejme0803081 · Cited by 34
Grabe, H., Bapuraj, J. R., Wesolowski, J. R., Parmar, H. A., & Trobe, J. D. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e318223d0a9 · Cited by 32
Effects of Topical Brinzolamide on Infantile Nystagmus Syndrome Waveforms: Eyedrops for Nystagmus
Dell’Osso, L. F., Hertle, R. W., Leigh, R. J., Jacobs, J. B., King, S., & Yaniglos, S. S. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3182236427 · Cited by 32
Self-citationGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“31,90,91 The drug transduces RPE cells following subretinal injection.”
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps
Brimble, M. A., Cheng, P.-H., Winston, S. M., Reeves, I. L., Souquette, A., Spence, Y., Zhou, J., Wang, Y.-D., Morton, C. L., Valentine, M., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.008 · Cited by 30
La thérapie génique des rétinites pigmentaires héréditaires
Ducloyer, J., Meur, G. L., Cronin, T., Adjali, O., & Weber, M. (2020) · médecine/sciences · doi:10.1051/medsci/2020095 · Cited by 44
Inherited Eye Diseases with Retinal Manifestations through the Eyes of Homeobox Genes
Markitantova, Y. V., & Simirskii, V. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051602 · Cited by 33
“The use of directional genome editing using clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) systems is a promising area in biomedicine and ophthalmology for the treatment of inherited eye diseases This approach is being worked out to eliminate genetic defects leading to retinal development path…”
BackgroundAdvancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space
Wakshull, E., Quarmby, V. E., Mahler, H., Rivers, H. M., Jere, D., Ramos, M. F., Szczesny, P. J., Bechtold-Peters, K., Masli, S., & Gupta, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0128-y · Cited by 29
Chen, J., Lin, M., Li, N., Lin, L., & She, F. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.052 · Cited by 32
Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids
Liu, X., Chen, J., Liu, Z., Li, J., Yao, K., & Wu, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18429 · Cited by 32
Gene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Clérin, E., Marussig, M., Sahel, J., & Léveillard, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051625 · Cited by 33
“2 kb in order to avoid reverse packaging of vector sequences during the production of the viral particles by the use of a long stuffer sequence [133].”
Efficacious and Safe Tissue-Selective Controlled Gene Therapy Approaches for the Cornea
Mohan, R. R., Sinha, S., Tandon, A., Gupta, R., Tovey, J. C. K., & Sharma, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018771 · Cited by 28
“The ocular gene therapy clinical trials carried-out with AAV serotype 2 (AAV2) for the retina have not reported any severe immune or inflammatory reactions among patients with used AAV vectors [38–40].”
Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27
“Antibody titer to RPE65 was determined with an ELISA by modification of previously described methods.(10,23,24) The positive control was the PETLET rabbit anti-mouse RPE65 antibody (gift of Dr.”
MethodSelf-citationTransduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection
Giove, T. J., Sena-Esteves, M., & Eldred, W. D. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.011 · Cited by 27
“For example, several studies have demonstrated the efficacy of AAV-mediated gene therapy for treating Leber congenital amaurosis (LCA) in various animal models, including nonhuman primates (Bennicelli et al., 2008; Jacobson et al., 2006; Pawlyk et al., 2005).”
Cai, B., Sun, S., Li, Z., Zhang, X., Ke, Y., Yang, J., & Li, X. (2018) · Human Genetics · doi:10.1007/s00439-018-1933-9 · Cited by 30
Patrício, M. I., Cox, C. I., Blue, C. E., Barnard, A. R., de la Cámara, C. M.-F., & MacLaren, R. E. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.005 · Cited by 28
“RPE65, Fischer et al.9 reported that twice as many vector genomes are lost when loading rAAV8-based viral vector solutions in the injection g Passage through the Surgical Device system without adding 0.001% PF68.”
BackgroundMethodInfluentialPotential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Recent advances in ocular gene therapy
Chung, D. C., Lee, V., & Maguire, A. M. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32832f802a · Cited by 30
Self-citationQuantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes
Xu, J., DeVries, S. H., & Zhu, Y. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.063 · Cited by 25
Negrete, A., & Kotin, R. M. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln034 · Cited by 25
“congenital amaurosis, a cause of blindness [24])”
Thurtell, M. J., Dell’Osso, L. F., Leigh, R. J., Matta, M., Jacobs, J. B., & Tomsak, R. L. (2010) · The Open Ophthalmology Journal · doi:10.2174/1874364101004010042 · Cited by 25
Self-citationNakazawa, M., Hara, A., & Ishiguro, S.-I. (2019) · BioMed Research International · doi:10.1155/2019/8276140 · Cited by 29
Bennett, J., & Maguire, A. M. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041307 · Cited by 28
Self-citationChan, A., Maturana, C. J., & Engel, E. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114598 · Cited by 24
“Since both FDA approved gene therapy drugs Luxturna and Zolgensma (LUXTURNA® (voretigene neparvovec-rzyl) HCP [WWW Document]; ZOLGENSMA® (onasemnogene abeparvovec-xioi) [WWW Document]) use Poloxamer 188 (Pluronic F68) to store their AAV and it has been shown to be efficacious in vector delivery in dogs and mice (Benni…”
BackgroundThe new landscape of retinal gene therapy
Ku, C. A., & Pennesi, M. E. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31842 · Cited by 26
“…& Gal, 1999) provided detailed characterization of the disease phenotype (Katz et al., 2005; Katz & Redmond, 2001), and in vivo models to assess therapeutic efficacy (Acland et al., 2005; Bennicelli et al., 2008; Le Meur et al., 2007; Narfstrom, Vaegan Katz, Bragadottir, Rakoczy, & Seeliger, 2005).”
BackgroundHiemenz, C., Pacios-Michelena, A., Helbig, C., Vezočnik, V., Strebl, M., Nikels, F., Hawe, A., Garidel, P., & Menzen, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.009 · Cited by 24
Zhou, J.-M., Yang, X. J., Wright, J. F., High, K. A., Couto, L. B., & Qu, G. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.01.013 · Cited by 25
Self-citationZheng, Q., Ren, Y., Tzekov, R. T., Zhang, Y., Chen, B., Hou, J., Zhao, C., Zhu, J., Zhang, Y., Dai, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044855 · Cited by 25
“[16] reported RPE65 protein expression after the administration of a AAV2-RPE65 gene.”
BackgroundArgyriou, C., Polosa, A., Song, J. Y., Omri, S., Steele, B. H., Cécyre, B., McDougald, D. S., Pietro, E. D., Bouchard, J., Bennett, J., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.002 · Cited by 21
Self-citationProspectives for Gene Therapy of Retinal Degenerations
Thumann, G. (2012) · Current Genomics · doi:10.2174/138920212801619214 · Cited by 27
“The natural occurrence of mutation in the RPE65 gene in dogs [46] and mice [47, 48] that mimics human LCA has made possible the development of gene therapy protocols for the successful treatment of these animals [49-56] as well as the application of these gene therapy protocols to the human disease.”
BackgroundPensado, A., Diaz-Corrales, F. J. J., de la Cerda, B., Valdés-Sánchez, L., del Boz, A. A., Rodríguez–Martínez, D., García-Delgado, A. B., Seijo, B., Bhattacharya, S. S., & Sánchez, A. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.06.007 · Cited by 23
Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis
Gross, A. L., Gray‐Edwards, H. L., Bebout, C. N., Ta, N. L., Nielsen, K., Brunson, B. L., Mercado, K. R. L., Osterhoudt, D. E., Batista, A. R., Maitland, S. A., et al. (2021) · Brain · doi:10.1093/brain/awab309 · Cited by 21
Matet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2066169 · Cited by 20
“Preclinical animal studies in mice and canines harbouring the RPE65 mutant showed visual rescue by subretinal injections of AAVRPE65 [53,54].”
BackgroundSubretinal gene therapy delays vision loss in a Bardet-Biedl Syndrome type 10 mouse model
Hsu, Y., Bhattarai, S., Thompson, J. M., Mahoney, A., Thomas, J., Mayer, S. K., Datta, P., Garrison, J. E., Searby, C. C., Vandenberghe, L. H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.007 · Cited by 24
“5 10(8) vg/mL).(36) In that particular study, dose escalation frommice to dogs entailed an 82.”
BackgroundCorydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
Using the NAFX to Measure the Effectiveness over Time of Gene Therapy in Canine LCA
Jacobs, J. B., Dell’Osso, L. F., Wang, Z. I., Acland, G. M., & Bennett, J. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3387 · Cited by 22
“Further details for this cohort have been published elsewhere.(24)”
Self-citationBurnight, E. R., Wiley, L. A., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017434 · Cited by 23
“For instance, gene replacement with an adeno-associated virus (AAV) vector to treat RPE65-associated LCA (LCA2) was largely successful in both the Rpe652/2 mouse and the large Briard dog model of the disease (Bennicelli et al. 2008).”
BackgroundMethodInfluentialLhériteau, E., Libeau, L., Mendes-Madeira, A., Deschamps, J.-Y., Weber, M., Le Meur, G., Provost, N., Guihal, C., Moullier, P., & Rolling, F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.46 · Cited by 18
Prantner, A. M., & Maar, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280242 · Cited by 22
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
Gene Therapy for Rare Neurological Disorders
Flotte, T. R., & Gessler, D. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2543 · Cited by 23
“As mentioned above, earlier studies did not find a transgene- directed immune response and only transient reactivity against the capsid in dogs.(98) However, the safety and feasibility of redosing were revisited before the attempt was made in humans, underscoring its importance.”
BackgroundResultInsight Into the Degradation Pathways of an AAV9
Rodriguez, A., Jalimarada, S. S., Banazadeh, A., Afroz, S., Ali, A., Deng, K., Huang, L., Galibert, L., Singh, R., & Zhou, C. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.05.034 · Cited by 16
Ameline, B., Tshilenge, K., Weber, M., Biget, M., Libeau, L., Caplette, R., Mendes-Madeira, A., Provost, N., Guihal, C., Picaud, S. A., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.63 · Cited by 17
Nikonov, S. S., Aravand, P., Lyubarsky, A., Nikonov, R., Luo, A. J., Wei, Z., Maguire, A. M., Phelps, N. T., Shpylchak, I., Willett, K. L., et al. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.5.24 · Cited by 16
Self-citationRetinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“Subretinal administration of AAV2 packaging the Rpe65 gene under a hybrid cytomegalovirus immediate early enhancer/chicken b-actin promoter provided vision rescue as measured through ERGs in 1- to 2-month-old Rpe65-KO and rd12 mice [29].”
MethodDarbey, A. L., Rebourcet, D., Curley, M. K., Kilcoyne, K. R., Jeffery, N., Reed, N., Milne, L., Roesl, C., Brown, P., & Smith, L. B. (2020) · Andrology · doi:10.1111/andr.12915 · Cited by 16
Optimized OPA1 Isoforms 1 and 7 Provide Therapeutic Benefit in Models of Mitochondrial Dysfunction
Maloney, D. M., Chadderton, N., Millington‐Ward, S., Palfi, A., Shortall, C., O’Byrne, J. J., Cassidy, L., Keegan, D., Humphries, P., Kenna, P. F., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.571479 · Cited by 17
“AAV containing fractions were dialyzed against PBS supplemented with Pluronic F68 (0.001%; Bennicelli et al., 2008).”
MethodInfluentialRamy, S., Ueda, Y., Nakajima, H., Hiroi, M., Hiroi, Y., Torisu, T., & Uchiyama, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.022 · Cited by 16
Bennett, J., Chung, D. C., & Maguire, A. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00013-2 · Cited by 20
“This allows instruments to be introduced under direct visualization with an anterior approach (Acland et al., 2001, 2005; Amado et al., 2010; Bennicelli et al., 2008).”
MethodSelf-citationModulation of transgene expression in retinal gene therapy by selective laser treatment.
Lavinsky, D., Chalberg, T., Mandel, Y., Huie, P., Dalal, R., Marmor, M., & Palanker, D. (2013) · Investigative Ophthalmology and Visual Science · doi:10.1167/iovs.12-10933 · Cited by 14
Thermostability and in vivo performance of AAV9 in a film matrix
Doan, T. N. K., Le, M. D., Bajrovic, I., Celentano, L., Krause, C., Balyan, H. G., Svancarek, A., Mote, A., Tretiakova, A. P., Samulski, R. J., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00212-6 · Cited by 15
Isgrig, K. T., Cartagena‐Rivera, A. X., Wang, H. J., Grati, M., Fernandez, K. A., Friedman, T. B., Belyantseva, I. A., & Chien, W. W. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.014 · Cited by 14
“…and puri fi ed by micro-fl uidization, fi ltration, cation exchange chromatography, density gradient ultracentrifugation, and dia fi ltration in PBS. 44,45 The puri-fi ed virus was passed through a 0.22-m m fi lter using a sterile 60-mL syringe and syringe fi ltered and stored frozen at (cid:1) 80…”
InfluentialOshitari, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910485 · Cited by 17
“Several basic studies indicate that the recombinant AAV-mediated RPE65 gene transfer to the retina successfully restores visual function in animal models of LCA [141–144].”
BackgroundNelles, M., Stieger, K., Preising, M. N., Kruse, J., & Lorenz, B. (2015) · Ophthalmic Research · doi:10.1159/000435887 · Cited by 15
Hines-Beard, J., Desai, S., Haag, R., Esumi, N., D’Surney, L., Parker, S., Richardson, C. R., & Rex, T. S. (2013) · Current Gene Therapy · doi:10.2174/15665232113139990024 · Cited by 14
“Significant progress has been made recently in treating certain forms of inherited retinal degenerations with gene specific approaches [1-3].”
BackgroundSelf-citationTurco, F., Wegelius, A., Lind, O., Norrman, N., Magnusson, A.-C., Sund-Lundström, C., Norén, B., Hedberg, J. J., & Palmgren, R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.010 · Cited by 14
“As only minimal loss of viral particles was detected in the flowthrough (circa 3%, Table S1), we speculate this is likely to be due to viral particles binding to various inert surfaces and/or sticking to cell debris as previously reported elsewhere.(11,17,19,34)”
ResultSom, M., Gikanga, B., Kanapuram, V., & Yadav, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.024 · Cited by 13
Petersen‐Jones, S. M., Annear, M. J., Bartoe, J. T., Mowat, F. M., Barker, S. E., Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0631-0_24 · Cited by 12
AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes
Chaqour, B., Duong, T. T., Yue, J., Liu, T., Camacho, D., Dine, K. E., Esteve-Rudd, J., Ellis, S., Bennett, J., Shindler, K. S., et al. (2024) · Gene Therapy · doi:10.1038/s41434-023-00436-8 · Cited by 13
“All AAV vectors were packaged using previously described methods and puri fi ed with CsCl gradient [35].”
Self-citationGene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 14
“…dogs for a severe recessive retinopathy, LCA (Acland et al., 2001 , 2005 ; Narfstrom et al., 2003 , 2005 , 2008 ; Jacobson et al., 2006 ; Le Meur et al., 2007 ; Bennicelli et al., 2008 ; Annear et al., 2011 ) have paved the way for many further preclinical studies for other recessive retinopathies.”
BackgroundZobor, D., Brühwiler, B. V. T., Zrenner, E., Weisschuh, N., & Kohl, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108915 · Cited by 16
Day blind sheep and the importance of large animal disease models
Komáromy, A. M. (2010) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.07.007 · Cited by 15
Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies
Kish, W. S., Lightholder, J., Zeković, T., Berrill, A., Roach, M. K., Wellborn, W. B., & Vorst, E. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28737 · Cited by 12
“In alignment with our findings, it was previously reported that surfactants reduce adsorption of rAAV capsids to surfaces, increasing yields (Bennicelli et al., 2008; Patricio et al., 2020).”
Available Evidence on Leber Congenital Amaurosis and Gene Therapy
Alkharashi, M., & Fulton, A. B. (2016) · Seminars in Ophthalmology · doi:10.1080/08820538.2016.1228383 · Cited by 16
“A decade ago, preclinical proof-of-concept studies for RPE65 gene therapy were conducted using a naturally occurring canine model(53) and murine models.(54,55) Based on the success of these animal studies, three independent clinical trials (NCT00516477, NCT006437473, and NCT00481546) were conducted at the same time to…”
BackgroundClinical applications of retinal gene therapies
Fu, X., Huu, V. A. N., Duan, Y., Kermany, D., Valentim, C. C. S., Zhang, R., Zhu, J., Zhang, C. L., Sun, X., & Zhang, K. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby004 · Cited by 13
“Additional follow-ups found that cortical responses, assessed by functional magnetic resonance imaging (fMRI), were significantly improved and visually guided behavior was recovered in treated dogs, suggesting that retinal signals were correctly propagated to the visual processing centers of the brain.(28,31,32,34) Un…”
BackgroundGene therapy approaches for the treatment of retinal disorders.
Petit, L., & Punzo, C. (2016) · PubMed · Cited by 17
Sather, R., Ihinger, J., Simmons, M., Lobo, G. P., & Montezuma, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021253 · Cited by 15
“The utilization of the wild-type RPE65 complementary DNA in the RPE target cells of animal models and humans via an adeno-associated viral vector for supplementation therapy has shown to significantly improve visual function in Phase I–III trials [39,40].”
MethodBonilha, V. L., Rayborn, M. E., Li, Y., Grossman, G., Berson, E. L., & Hollyfield, J. G. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7973 · Cited by 12
Adeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 11
Combes, R. D., & Shah, A. B. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400302 · Cited by 14
Identification of Key Residues Determining Isomerohydrolase Activity of Human RPE65
Takahashi, Y., Moiseyev, G. P., & Ma, J.-X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558619 · Cited by 10
Chadderton, N., Palfi, A., Maloney, D. M., Carrigan, M., Finnegan, L. K., Hanlon, K. S., Shortall, C., O’Reilly, M., Humphries, P., Cassidy, L., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020322 · Cited by 9
Clinical and pharmacovigilance safety evaluation of LUXTURNA ® (voretigene neparvovec-rzyl)
Simoens, D., Shravah, V., Jones, W. K., & Kaja, S. (2025) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2025.2573463 · Cited by 13
“Preclinical studies in dogs and nonhuman primates optimized dosage and confirmed safety [22,23,30,31]. toxicology studies showed that high sub-retinal AAv doses were generally well tolerated, although the observed immune responses were varied [8]. while some structural retinal changes were…”
Fischer, M. D. (2016) · Ophthalmologica · doi:10.1159/000445782 · Cited by 10
Salvetti, A. P., Patrício, M. I., Barnard, A. R., Orlans, H. O., Hickey, D. G., & MacLaren, R. E. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.4.4 · Cited by 10
Matsevich, C., Gopalakrishnan, P., Chang, N., Obolensky, A., Beryozkin, A., Salameh, M., Kostic, C., Sharon, D., Arsenijévic, Y., & Banin, E. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.011 · Cited by 10
Palfi, A., Yesmambetov, A., Millington‐Ward, S., Shortall, C., Humphries, P., Kenna, P. F., Chadderton, N., & Farrar, G. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00891 · Cited by 9
Hinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 13
Dong, Y., Cai, X., Wu, Y., Liu, Y., Deng, L., & Chen, H. (2017) · PubMed · Cited by 8
Gene therapy: Progress in childhood disease
Ginn, S. L., & Alexander, I. E. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02204.x · Cited by 10
A non‐surgical method for subretinal delivery by trans‐scleral microneedle injection
Hejri, A., Chrenek, M. A., Goehring, N. T., Bowland, I. I., Noel, R. K., Yan, J., Nickerson, J. M., & Prausnitz, M. R. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10755 · Cited by 8
“49, 52”
Extracorporeal Delivery of rAAV with Metabolic Exchange and Oxygenation
Bieber, S. D., Halldorson, J. B., Finn, E. E., Ahmad, S., Chamberlain, J. S., & Odom, G. L. (2013) · Scientific Reports · doi:10.1038/srep01538 · Cited by 6
“Proceedings of the National Academy of Sciences of the United States of America 95 (24), 14384–8 (1998).”
Klein, D., Mendes-Madeira, A., Schlegel, P., Rolling, F., Lorenz, B., Haverkamp, S., & Stieger, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086304 · Cited by 10
Fujinami, K., Akiyama, K., Tsunoda, K., Ito, S., Seko, N., & Yamamoto, S. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100876 · Cited by 7
“4,12,13,21,22 28 The efficacy and safety of VN have been confirmed in 2 phase I studies (101 study, 201 study) 25,26 and in a phase III study (301 study) 29 — 31 conducted in the United States.”
Vitreoretinal disease in the coming decade
Chiang, A., & Haller, J. A. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32833866db · Cited by 8
Mason, J. B., Gurda, B. L., Engiles, J. B., Hankenson, K. D., Wilson, J. M., & Richardson, D. W. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.199 · Cited by 6
“In a previous study (Bennicelli et al., 2008), vector recovery was assessed in vitro in the presence or absence of surfactant after vector dilution and passage through injection devices.”
Benefits of gene therapy for both eyes
MacLaren, R. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30783-8 · Cited by 6
Analysis of the impact of pluronic acid on the thermal stability and infectivity of AAV6.2FF
Thomas, S. P., Spinelli, M. M., Rghei, A. D., Lopes, J. A., Zielinska, N., McLeod, B. M., Pei, Y., Zhang, W., Thébaud, B., Karimi, K., et al. (2024) · BMC Biotechnology · doi:10.1186/s12896-024-00853-6 · Cited by 8
“…could be because PF-68 is thought to prevent protein aggregation or precipitation upon shear stress or when exposed to air-water interface [18, 36, 37], which for AAV has been reported to alter biodistribution or immunogenicity of the vector [38], and surface adsorption during vector…”
BackgroundManufacturing Considerations and Challenges for AAV Ocular Gene Therapy
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Rivers, H. M., Feng, S., Shah, D., & Slater, N. K. H. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_22 · Cited by 5
Amato, A., Tschetter, W. W., Everett, L. A., Bailey, S. T., Lauer, A. K., Yang, P. G., & Pennesi, M. E. (2024) · Documenta Ophthalmologica · doi:10.1007/s10633-024-09987-6 · Cited by 5
O’Neill, N., Meng, M., Chaqour, B., Dine, K. E., Sarabu, N., Pham, J. C., Shindler, K. S., & Ross, A. G. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.8.37 · Cited by 5
Skaripa-Koukelli, I., Schmidt, O., Ketterer, C., Lardenoije, R., Qutaishat, S., Machado, A. H. E., Dürr, C., van Haasteren, J., Goldbach, P., Fuchsloch, L., et al. (2025) · AAPS Open · doi:10.1186/s41120-025-00131-5 · Cited by 4
Metadata
- Authors
- Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., Wei, Z., Qu, G., Zhou, S., Zeiss, C., Arruda, V. R., Acland, G. M., Dell'Osso, L. F., High, K. A., Maguire, A. M., & Bennett, J.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Case Western Reserve University (US)
- Yale University (US)
- Cornell University (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 458-465
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2842085
- OpenAlex
- W2035101755
- Cited by
- 267
- References
- 25
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 16 · 2023: 13 · 2022: 14 · 2021: 15 · 2020: 17 · 2019: 13 · 2018: 10 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 18 · 2013: 11 · 2012: 16
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- F. M. Kirby Foundation
- Research to Prevent Blindness
- Macula Vision Research Foundation
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY015398, R01EY006855, K12EY015398)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Leber congenital amaurosis, RPE65, AAV2, gene therapy, adeno-associated virus vectors, subretinal injection, retinal pigment epithelium, vector safety, electroretinogram, visual acuity, nystagmus, canine model, vector production
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Dogs, Electroretinography, Eye Proteins, Genetic Vectors, Immunohistochemistry, Mice, Knockout, cis-trans-Isomerases, Optic Atrophy, Hereditary, Leber, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.